נק' מוניטין:
58,703
Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
Franchek Drobnic1*, Joan Riera1, Giovanni Appendino2, Stefano Togni3, Federico Franceschi3, Xavier Valle4, Antoni Pons5 and Josep Tur5
* Corresponding author: Franchek Drobnic [email protected]
Author Affiliations
1 Olympic Training Centre (CAR), Barcelona, Spain
2 Università degli Studi del Piemonte Orientale, Novara, Italy
3 Indena s.p.a., Milano, Italy
4 University of Barcelona, School of Sports Medicine, Medical Services, FCBarcelona, Spain
5 Department Biologia Fonamental i de la Salut, University of Illes Balears, Mallorca, Spain
Journal of the International Society of Sports Nutrition 2014, 11:31 doi:10.1186/1550-2783-11-31
Received: 13 March 2014
Accepted: 11 June 2014
Published: 18 June 2014
Abstract
Background
Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise
Methods
This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded.
Results
Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed
Conclusions
Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin.
http://www.jissn.com/content/pdf/1550-2783-11-31.pdf
Franchek Drobnic1*, Joan Riera1, Giovanni Appendino2, Stefano Togni3, Federico Franceschi3, Xavier Valle4, Antoni Pons5 and Josep Tur5
* Corresponding author: Franchek Drobnic [email protected]
Author Affiliations
1 Olympic Training Centre (CAR), Barcelona, Spain
2 Università degli Studi del Piemonte Orientale, Novara, Italy
3 Indena s.p.a., Milano, Italy
4 University of Barcelona, School of Sports Medicine, Medical Services, FCBarcelona, Spain
5 Department Biologia Fonamental i de la Salut, University of Illes Balears, Mallorca, Spain
Journal of the International Society of Sports Nutrition 2014, 11:31 doi:10.1186/1550-2783-11-31
Received: 13 March 2014
Accepted: 11 June 2014
Published: 18 June 2014
Abstract
Background
Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise
Methods
This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded.
Results
Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed
Conclusions
Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin.
http://www.jissn.com/content/pdf/1550-2783-11-31.pdf
